Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug

Seeking AlphaApr 23 10:29 ET

Private Equity Firms Among Solid Biosciences Inc.'s (NASDAQ:SLDB) Largest Stockholders and Were Hit After Last Week's 13% Price Drop

Key Insights Solid Biosciences' significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 5 investors have a majorit

Simply Wall StApr 11 10:25 ET

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, t

Solid BiosciencesApr 3 00:00 ET

Express News | Solid Biosciences Shares Are Trading Higher After the Company Received Rare Pediatric Disease Designation for SGT-003 From the FDA

Moomoo 24/7Apr 2 08:44 ET

Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label

Solid Biosciences (SLDB) said Monday its gene therapy candidate SGT-003 for Duchenne muscular dystrophy has received rare pediatric disease designation from the US Food and Drug Administration. The de

MT NewswiresApr 1 14:04 ET

Solid Biosciences Receives Rare Pediatric Disease Designation From the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. –– Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 –CHARLESTOWN, Mass., Apri

Solid BiosciencesApr 1 00:00 ET